SNS-595 AND METHODS OF USING THE SAME

1 . A method for treating ovarian cancer comprising administering to a patient having ovarian cancer a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.

2 . The method of claim 1 wherein the dose is 10 mg/m 2 -100 mg/m 2 .

3 . The method of claim 1 wherein the dose 30 mg/m 2 -75 mg/m 2 .

4 . The method of claim 1 wherein the dose is 40 mg/m 2 -80 mg/m 2 .

5 . The method of claim 1 wherein the dose is 50 mg/m 2 -90 mg/m 2 .

6 - 8 . (canceled)

9 . The method of claim 1 additionally comprising administering to said patient a therapeutically effective dose of a supportive care agent.

10 . The method of claim 9 wherein the supportive care agent is an antiemetic.

11 . (canceled)

12 . A method for treating ovarian cancer comprising: i) administering a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer; ii) waiting a period of at least one day where the patient is not administered any (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid; iii) administering another dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to the patient;

13 . The method of claim 12 wherein the period is at least 2 days.

14 . The method of claim 12 wherein the period is at least 3 days.

15 . The method of claim 12 wherein the period is at least 6 days.

16 . The method of claim 12 wherein the period is at least 13 days.

17 . The method of claim 10 wherein the period is at least 20 days.

18 . The method of claim 10 wherein the period is at least 27 days.

19 . A method for treating ovarian cancer comprising administering a weekly dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer.

20 . A method for treating ovarian cancer comprising administering a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid once every three weeks to a patient having ovarian cancer.

21 . A method for treating ovarian cancer comprising a cycle wherein the cycle comprises administering a dose of 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a subject having ovarian cancer once every week for three weeks followed by a period of at least two weeks where no (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is administered to said subject and wherein the cycle is repeated a plurality of times.

22 - 26 . (canceled)